Detailansicht

Wissensnetz

Person

Marc Pawlitzki

Arzt

Name	Marc Pawlitzki
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	PD Dr. med.
Beruf	Arzt (charakteristischer Beruf) Neurologe
Variante	M. Pawlitzki
Beziehung	Universitätsklinikum Düsseldorf
Datensatztyp	Person
GND-Nummer	1155421779
Datensatz-ID	1155421779
Beteiligt an alle anzeigen Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD? Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019 Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Eculizumab versus rituximab in generalised myasthenia gravis Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation Pain, depression, and quality of life in adults with MOG-antibody–associated disease CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation Multimodale Analyse von kernspintomographischen Parametern bei Patienten mit Multipler Sklerose

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Marc Pawlitzki

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study

Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?

Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments

Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Eculizumab versus rituximab in generalised myasthenia gravis

Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Intravenous methadone causes acute toxic and delayed inflammatory encephalopathy with persistent neurocognitive impairments

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation

Pain, depression, and quality of life in adults with MOG-antibody–associated disease

CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis

Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation

Multimodale Analyse von kernspintomographischen Parametern bei Patienten mit Multipler Sklerose